Navigation Links
MediSapiens Gets $ 1 Million for World's First Personalized Cancer Medicine Software
Date:6/1/2010

HELSINKI, June 1, 2010 /PRNewswire/ -- MediSapiens, world's first software company for personalized cancer medicine in oncology clinics and drug development, completed $ 1 million (EUR 0.8 million) seed round investment from Veraventure, ETFIII advised by Eqvitec Partners, VTT Ventures and Lifeline Ventures.

MediSapiens is based on scientific research at the VTT Technical Research Centre of Finland and its collaborators. MediSapiens hosts world's largest unified gene expression database of human tissues and diseases. This enables scientists to understand the role of human genes in health and disease - to be applied in helping oncologists in choosing optimal treatments and biopharmaceutical companies in developing next generation personalized medicines.

"The latest research - such as The Cancer Genome Atlas funded by the NIH - demonstrates that every patient's cancer is a complex, unique combination of genetic mutations and abnormally expressed genes. The MediSapiens software gives personalized and clinically applicable insight into each patient's cancer," says Tommi Pisto, CEO and Co-founder of MediSapiens.

"Making use of the data produced by the global scientific community provides a new and significant opportunity to understand cancer. Oncologists can benefit when these reference datasets are used to interpret molecular profiling results for individual patients," comments Professor Olli Kallioniemi, MediSapiens board member and director of the Institute for Molecular Medicine Finland (FIMM).

About MediSapiens

MediSapiens, the world's first software company for personalized cancer medicine in oncology clinics and new drug development, hosts world's largest unified gene expression database. With the data online, oncologists have access to evaluate individual patient's genetic signature for the optimized treatment strategy, and scientists understand how genes work across all human tissues. Company's bioinformatics science and peer-reviewed data is based on the research since 2005 by VTT Technical Research Centre of Finland and its collaborators. Visit http://www.medisapiens.fi for more information.

About Veraventure

Veraventure, with assets under management exceeding EUR 100m, is one of the largest early stage funds in Nordic countries. Veraventure makes direct investments in early-stage research, development and innovation intensive enterprises. It also acts as the hub for early-stage venture capital and angel investors as it manages national business angel network with over 100 registered angel investors. Visit http://www.veraventure.fi/company for more information.

About Eqvitec

Eqvitec Partners is one of the largest technology oriented private equity firms in Northern Europe. The company was founded in 1997 and employs 10 investment professionals in Helsinki and Stockholm. Eqvitec Partners currently advises three funds with a total capital base of over EUR 300 million. The funds invest in technology companies in the expansion stage. At the moment the funds have investments in 30 companies and have carried out over 40 exits. Visit http://www.eqvitec.com for more information.

About VTT Ventures

VTT Ventures Ltd is a development company that generates and develops spin-offs based on VTT's technology. We work closely with more than 2,500 VTT researchers and scientists to find the most valuable new technologies to commercialize. Through us, entrepreneurs have access to innovative ideas and know-how of more than 300 patent families. This is the bases for the dealflow that enables us to create growth companies with global potential. Visit http://www.vttventures.fi for more information.

About Lifeline Ventures

Lifeline Ventures, a venture accelerator and early-stage investment fund, co-creates growth companies in health and technology. Being entrepreneurs, we are active team members for an early-stage venture for 12-24 months. Visit http://www.lifelineventures.com for more information.

    Media contact:

    Timo Ahopelto
    VP Strategy
    MediSapiens
    Email: timo.ahopelto@medisapiens.fi
    Telephone: +358-400-569-628


'/>"/>
SOURCE MediSapiens Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Alexza Secures $25 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd.
2. Phreesia to Accelerate Growth with $16 Million Investment Led by Ascension Health Ventures
3. Karmanos Cancer Institutes Delphinus Receives $8 Million in Venture Capital for Product Development of Breast Cancer Imaging Tool
4. Genzyme Corp. Signs Consent Decree to Correct Violations at Allston, Mass., Manufacturing Plant and Give up $175 Million in Profits
5. Ortho-McNeil Pharmaceutical, LLC Pleads Guilty to Illegal Promotion of Topamax and is Sentenced to Criminal Fine of $6.14 Million
6. AstraZeneca Donates $1 Million for Christiana Care Health Systems Wilmington Hospital Project
7. Winner Medical Group Inc. Announces Exercise of Over-Allotment Option Bringing Aggregate Net Proceeds of the Public Offering to $8.8 Million
8. Breathe Technologies Secures $23 Million in Series C Financing
9. ThromboGenics and BioInvent to Receive EUR10 Million Milestone as Partner Roche Begins New Clinical Study with TB-403
10. Curexo Technology Corporation Raises $13.2 Million
11. Alexza Executes $15 million Working Capital Loan with Hercules Technology Growth Capital, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... Minn. , July 20, 2017  Prime Therapeutics LLC ... Jonathan Gavras , M.D., following today,s Institute for Clinical and ... report on the effectiveness and value of abuse-deterrent formulations ... on the policy roundtable at the meeting. ... not a material cost benefit to the use of abuse-deterrent ...
(Date:7/17/2017)... ORLANDO, Fla. , July 17, 2017  MedX ... - branded medical testing, strengthening and rehabilitation equipment, today ... Back Machine Program. MedX is considered the gold standard ... world leader in specialized medical strengthening equipment. ... into a lease with the physician or practice who ...
(Date:7/14/2017)... -- Endo International plc (NASDAQ: ENDP ) will announce ... of its senior management team will host a conference call and ... The dial-in number to access the call is ... the passcode is 45397076. Please dial in 10 minutes prior to ... A replay of the call will be available from August 8, ...
Breaking Medicine Technology:
(Date:7/27/2017)... ... ... The Los Angeles leg of the US movie premier of the Man in the Camo ... the Clive Davis Theater inside the Grammy Museum Located in downtown Los Angeles in the ... Welsh rock musician, Mike Peters (of The Alarm), his rise to fame, battle with cancer ...
(Date:7/27/2017)... ... 27, 2017 , ... Cremations recently surpassed traditional burials for the first time ... expected to continue with over 70% of Americans projected to choose cremation by 2030. ... that enable families to celebrate the life of a lost loved one in different ...
(Date:7/26/2017)... ... ... greater Bay Area roller derby leagues are partnering with Brown Paper Tickets and the American ... blood drives in California, beginning July 29. Make ‘Em Bleed roller derby blood drives have ... have helped to save up to 2700 lives. , “The Make ‘Em Bleed blood drives ...
(Date:7/26/2017)... Maryland (PRWEB) , ... July ... ... Society for Pharmaceutical Engineering (ISPE) will host its 2017 Process Validation ... These concurrent events offer comprehensive solutions to process validation lifecycle challenges faced ...
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... ... dogs and cats has opened in Jupiter. The state of the art ... and class leading treatments with a goal of providing heart patients longer lives. ...
Breaking Medicine News(10 mins):